A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia
MetadataShow full item record
AbstractGlioblastoma (GBM) is the most common invasive malignant brain tumour in adults. It is traditionally investigated in vitro by culturing cells as a monolayer (2D culture) or as neurospheres (clusters enriched in cancer stem cells) but neither system accurately reflects the complexity of the three-dimensional (3D) chemoresistant microenvironment of GBM. Using three GBM cell-lines (U87, U251, and SNB19), the effect of culturing cells in a Cultrex-based basement membrane extract (BME) [3D Tumour Growth Assay (TGA)] on morphology, gene expression, metabolism, and temozolomide chemoresistance was investigated. Cells were easily harvested from the 3D model and cultured as a monolayer (2D) and neurospheres. Indeed, the SNB19 cells formed neurospheres only after they were first cultured in the 3D model. The expression of CD133 and OCT4 was upregulated in the neurosphere and 3D assays respectively. Compared with cells cultured in the 2D model, cells were more resistant to temozolomide in the 3D model and this resistance was potentiated by hypoxia. Taken together, these results suggest that micro-environmental factors influence GBM sensitivity to temozolomide. Knowledge of the mechanisms involved in temozolomide resistance in this 3D model might lead to the identification of new strategies that enable the more effective use of the current standard of care agents. PURPOSE MATERIALS AND METHODS RESULTS CONCLUSION
CitationMusah-Eroje A, Watson S (2019) 'A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia', Journal of Neuro-Oncology, 142 (2), pp.231-240.
JournalJournal of Neuro-Oncology
PubMed Central IDPMC6449313
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Green - can archive pre-print and post-print or publisher's version/PDF
- A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
- Authors: Ahmed EM, Bandopadhyay G, Coyle B, Grabowska A
- Issue date: 2018 Jun
- Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
- Authors: Liu YC, Lee IC, Chen PY
- Issue date: 2018 May
- Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
- Authors: Poon MW, Zhuang JT, Wong ST, Sun S, Zhang XQ, Leung GK
- Issue date: 2015 Dec
- The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
- Authors: Johannessen TC, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R
- Issue date: 2013 Mar
- Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
- Authors: Ngo MT, Harley BAC
- Issue date: 2019 Apr